Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors

被引：27

作者：

Bistola, Vasiliki ^{[1
]}

Lambadiari, Vaia ^{[2
]}

Dimitriadis, George ^{[2
]}

Ioannidis, Ioannis ^{[3
]}

Makrilakis, Konstantinos ^{[4
]}

Tentolouris, Nikolaos ^{[4
]}

Tsapas, Apostolos ^{[5
]}

Parissis, John ^{[1
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Med Sch, Heart Failure Unit,Dept Cardiol, Rimini 1 Chaidari, Athens 12461, Greece

[2] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Med Sch, Dept Internal Med 2, Athens, Greece

[3] Konstantopouleio Hosp, Diabet & Obes Ctr, Athens, Greece

[4] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Dept Propaedeut Internal Med 1, Diabet Ctr,Med Sch, Athens, Greece

[5] Aristotle Univ Thessaloniki, Clin Res & Evidence Based Med Unit, Thessaloniki, Greece

来源：

HEART FAILURE REVIEWS | 2018年 / 23卷 / 03期

关键词：

Type 2 diabetes mellitus; Cardiovascular outcomes; New antidiabetic drugs; GLP-1; agonists; DPP4; inhibitors; GLUCAGON-LIKE PEPTIDE-1; LEFT-VENTRICULAR DYSFUNCTION; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; ATRIAL-NATRIURETIC-PEPTIDE; TYPE-2; DIABETES-MELLITUS; CHRONIC HEART-FAILURE; IV INHIBITION; GLYCEMIC CONTROL; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE;

D O I：

10.1007/s10741-018-9674-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetes mellitus is a leading cause of cardiovascular morbidity and mortality worldwide. Traditional antidiabetic therapies targeting hyperglycemia reduce diabetic microvascular complications but have minor effects on macrovascular complications, including cardiovascular disease. Instead, cardiovascular complications are improved by antidiabetic medications (metformin) and other therapies (statins, antihypertensive medications) ameliorating insulin resistance and other associated metabolic abnormalities. Novel classes of antidiabetic drugs have proven efficacious in improving glycemia, while at the same time exert beneficial effects on pathophysiologic mechanisms of diabetes-related cardiovascular disease. In the present review, we will present current evidence of the cardiovascular effects of two new classes of antidiabetic medications, glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP4) inhibitors, focusing from mechanistic preclinical and clinical investigation to late-phase clinical testing.

引用

页码：377 / 388

页数：12

共 118 条

[1] Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial [J].